Compare Stocks → The system that called 2023’s top 7 stocks is at it again… (From WealthPress) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison OTCMKTS:ADYXOTCMKTS:CTTCOTCMKTS:DXTRQOTCMKTS:VSMD Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADYXAdynxx$0.00$0.00▼$0.00N/AN/AN/AN/ACTTCCalmare Therapeutics$0.00$0.00▼$0.02N/AN/AN/AN/ADXTRQDex Liquidating$0.03$0.03$0.02▼$0.16N/AN/AN/AN/AVSMDVasamed$0.00$0.00▼$0.00N/AN/AN/AN/ABeginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADYXAdynxx0.00%0.00%0.00%0.00%0.00%CTTCCalmare Therapeutics0.00%0.00%0.00%0.00%0.00%DXTRQDex Liquidating0.00%0.00%0.00%0.00%0.00%VSMDVasamed0.00%0.00%0.00%0.00%0.00%The Hard Truth About Investing For Retirement (Ad)Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.Click To Access This Powerful Training Right Now!MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADYXAdynxxN/AN/AN/AN/AN/AN/AN/AN/ACTTCCalmare TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ADXTRQDex LiquidatingN/AN/AN/AN/AN/AN/AN/AN/AVSMDVasamedN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADYXAdynxxN/AN/AN/AN/ACTTCCalmare TherapeuticsN/AN/AN/AN/ADXTRQDex LiquidatingN/AN/AN/AN/AVSMDVasamedN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADYXAdynxxN/AN/AN/AN/AN/AN/ACTTCCalmare TherapeuticsN/AN/AN/AN/AN/AN/ADXTRQDex LiquidatingN/AN/AN/AN/AN/AN/AVSMDVasamedN/AN/AN/AN/AN/AN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADYXAdynxxN/AN/A0.00N/AN/AN/AN/AN/AN/ACTTCCalmare TherapeuticsN/AN/A0.00N/AN/AN/AN/AN/AN/ADXTRQDex LiquidatingN/AN/A0.00∞N/AN/AN/AN/AN/AVSMDVasamedN/AN/A0.00N/AN/AN/AN/AN/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADYXAdynxxN/AN/AN/AN/AN/ACTTCCalmare TherapeuticsN/AN/AN/AN/AN/ADXTRQDex LiquidatingN/AN/AN/AN/AN/AVSMDVasamedN/AN/AN/AN/AN/AOwnershipInstitutional OwnershipCompanyInstitutional OwnershipADYXAdynxxN/ACTTCCalmare TherapeuticsN/ADXTRQDex LiquidatingN/AVSMDVasamedN/AInsider OwnershipCompanyInsider OwnershipADYXAdynxx17.40%CTTCCalmare Therapeutics17.50%DXTRQDex Liquidating10.43%VSMDVasamed8.02%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADYXAdynxx6N/AN/ANot OptionableCTTCCalmare Therapeutics7N/AN/ANot OptionableDXTRQDex LiquidatingN/AN/AN/ANot OptionableVSMDVasamedN/AN/AN/ANot OptionableVSMD, ADYX, CTTC, and DXTRQ HeadlinesNo headlines for this company have been tracked by MarketBeat.comCompany DescriptionsAdynxxOTCMKTS:ADYXAdynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.Calmare TherapeuticsOTCMKTS:CTTCCalmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.Dex LiquidatingOTCMKTS:DXTRQDextera Surgical Inc. designs and manufactures proprietary stapling devices for surgical procedures. The company's product consists of MicroCutter 5/80 use for transection and resection in urologic, thoracic and pediatric surgical procedures, as well as application for transection, resection and/or creation of anastomoses in the intestine and the transection of the appendix. Dextera Surgical Inc., formerly known as Cardica Inc., is headquartered in Redwood City, California.VasamedOTCMKTS:VSMDVasamed Incorporated designs, licenses, manufactures, and distributes products, software, and services for assessing and managing hemodynamic health in the United States. It offers SensiLase PAD-IQ, which supports skin perfusion pressure, pulse volume recording, and ankle brachial index calculation for Doppler-obtained pressures; and Wound Imaging & SmartDraw wound measurement systems. The company also provides PAD-IQ Studycast that provides rapid transmission of diagnostic tests to vascular specialist for interpretation of results and medically indicated therapeutic intervention; and custom carrying case to secure and protect the PAD-IQ system. It serves clinicians and patients. The company was founded in 1988 and is headquartered in Eden Prairie, Minnesota. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
